VD-PACE As Salvage and Bridging Therapy to Transplant and Cellular Therapy in Triple Class Relapsed/Refractory Multiple Myeloma

Patients that have triple-class relapsed/refractory multiple myeloma (RRMM) have relapsed on each of the following classes: immunomodulatory drugs, proteasome inhibitors, and an anti-CD38 monoclonal antibody. RRMM poses a significant challenge with poor prognosis due to limited options. We evaluated VD-PACE (bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) for efficacy and safety as salvage therapy in heavily pretreated RRMM.

https://www.astctjournal.org/article/S2666-6367(23)02280-7/fulltext?rss=yes

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Priyanka Venkatesh, Polina Bellman, Sara Shatnawi, Yara Shatnawi, Hira Shaikh, Christopher Sun Strouse, Shebli Atrash, Hamza Hashmi, Muhammad Umair Mushtaq, Nausheen Ahmed, Zahra Mahmoudjafari, Al-Ola Abdallah, Leyla Shune Tags: 534 Source Type: research